These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24975224)

  • 1. Oral phosphorus supplementation secondarily increases circulating fibroblast growth factor 23 levels at least partially via stimulation of parathyroid hormone secretion.
    Takasugi S; Akutsu M; Nagata M
    J Nutr Sci Vitaminol (Tokyo); 2014; 60(2):140-4. PubMed ID: 24975224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study.
    Kim HJ; Kim H; Shin N; Na KY; Kim YL; Kim D; Chang JH; Song YR; Hwang YH; Kim YS; Ahn C; Lee J; Oh KH;
    BMC Nephrol; 2013 May; 14():112. PubMed ID: 23705925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets.
    Alon US; Levy-Olomucki R; Moore WV; Stubbs J; Liu S; Quarles LD
    Clin J Am Soc Nephrol; 2008 May; 3(3):658-64. PubMed ID: 18256372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
    Kuczera P; Adamczak M; Wiecek A
    Clin Endocrinol (Oxf); 2014 Apr; 80(4):607-12. PubMed ID: 24111496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
    Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
    Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo.
    López I; Rodríguez-Ortiz ME; Almadén Y; Guerrero F; de Oca AM; Pineda C; Shalhoub V; Rodríguez M; Aguilera-Tejero E
    Kidney Int; 2011 Sep; 80(5):475-82. PubMed ID: 21525854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.
    Nagano N; Miyata S; Abe M; Kobayashi N; Wakita S; Yamashita T; Wada M
    Kidney Int; 2006 Feb; 69(3):531-7. PubMed ID: 16395276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinacalcet in the management of tumor-induced osteomalacia.
    Geller JL; Khosravi A; Kelly MH; Riminucci M; Adams JS; Collins MT
    J Bone Miner Res; 2007 Jun; 22(6):931-7. PubMed ID: 17352646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
    Nagano N
    Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
    Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
    Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium deficiency reduces circulating levels of FGF23.
    Rodriguez-Ortiz ME; Lopez I; Muñoz-Castañeda JR; Martinez-Moreno JM; Ramírez AP; Pineda C; Canalejo A; Jaeger P; Aguilera-Tejero E; Rodriguez M; Felsenfeld A; Almaden Y
    J Am Soc Nephrol; 2012 Jul; 23(7):1190-7. PubMed ID: 22581996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.
    Finch JL; Tokumoto M; Nakamura H; Yao W; Shahnazari M; Lane N; Slatopolsky E
    Am J Physiol Renal Physiol; 2010 Jun; 298(6):F1315-22. PubMed ID: 20200094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism.
    Serra AL; Wuhrmann C; Wüthrich RP
    Am J Kidney Dis; 2008 Dec; 52(6):1151-7. PubMed ID: 18950915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Murine Fetal Serum Phosphorus is Set Independent of FGF23 and PTH, Except in the Presence of Maternal Phosphate Loading.
    Sellars KB; Ryan BA; Hartery SA; Kirby BJ; Kovacs CS
    Endocrinology; 2021 Jan; 162(1):. PubMed ID: 33150413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
    Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
    Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
    Iguchi A; Kazama JJ; Yamamoto S; Yoshita K; Watanabe Y; Iino N; Narita I
    Nephron; 2015; 131(3):161-6. PubMed ID: 26551233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing dietary phosphorus intake from food additives: potential for negative impact on bone health.
    Takeda E; Yamamoto H; Yamanaka-Okumura H; Taketani Y
    Adv Nutr; 2014 Jan; 5(1):92-7. PubMed ID: 24425727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.
    Sánchez Fructuoso AI; Maestro ML; Calvo N; De La Orden V; Pérez Flores I; Vidaurreta M; Valero R; Fernández-Pérez C; Barrientos A
    Transplant Proc; 2012 Nov; 44(9):2551-4. PubMed ID: 23146451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinacalcet in hyperfunctioning parathyroid diseases.
    Imanishi Y; Inaba M; Kawata T; Nishizawa Y
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.